Agency
Halifax Hospital Medical Center
Halifax Hospital Medical Center was paid $26.97M by Medicaid between Jan 2018 and Dec 2024, across 265 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoHALIFAX HOSPITAL MEDICAL CENTER
DAYTONA BEACH, FL 32114
DAYTONA BEACH, FL 32114
33aNPI1811991227assigned 06/13/2005
33bProvider typeCase Management Agency
28Total paid$26.97M
24GClaims796,644
24DCodes billed265
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Management Agency providers in Florida
Rank by total paid#5 of 357
Median peer was paid$839K
This provider vs. median32×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,168 | $1.70M | |
| 2019 | 168,490 | $5.48M | |
| 2020 | 154,285 | $4.79M | |
| 2021 | 174,695 | $5.45M | |
| 2022 | 153,553 | $5.35M | |
| 2023 | 49,590 | $2.71M | |
| 2024incomplete | 17,863 | $1.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 61,392 | 55,333 | $4.63M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.9% | 16,971 | 5,707 | $2.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.4% | 29,163 | 24,904 | $1.99M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.5% | 15,092 | 14,438 | $1.49M |
| 80053 | Comprehensive metabolic panel | 5.4% | 35,471 | 26,829 | $1.46M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.7% | 15,495 | 10,618 | $1.26M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.2% | 8,193 | 5,875 | $1.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 11,847 | 10,181 | $974K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 4,618 | 4,079 | $864K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 7,505 | 6,218 | $672K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 9,418 | 3,190 | $661K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.4% | 16,786 | 5,849 | $659K |
253 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.2% | 2,770 | $593K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 2,436 | $426K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.4% | 6,297 | $391K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 4,201 | $363K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 3,497 | $352K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 9,866 | $330K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,747 | $290K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 1,633 | $284K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 4,997 | $275K |
| 96367 | <1% | 2,620 | $250K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,611 | $189K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,318 | $181K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,972 | $181K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 591 | $179K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,404 | $154K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,931 | $154K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,535 | $142K |
| 76818 | <1% | 2,063 | $141K | |
| 84703 | <1% | 13,494 | $136K | |
| G0378 | Hospital observation service, per hour | <1% | 10,716 | $133K |
| 92523 | <1% | 1,006 | $133K | |
| 96415 | <1% | 330 | $118K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,224 | $116K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,534 | $110K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,020 | $105K |
| 87081 | <1% | 3,548 | $105K | |
| 86850 | <1% | 3,503 | $104K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,437 | $104K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,950 | $98K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,932 | $90K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,861 | $80K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 133 | $78K |
| 81001 | <1% | 23,617 | $73K | |
| 59025 | Fetal non-stress test | <1% | 2,543 | $71K |
| 94664 | <1% | 3,445 | $71K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,289 | $66K |
| 12011 | <1% | 481 | $65K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 920 | $63K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 511 | $61K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,455 | $60K |
| 84702 | <1% | 3,503 | $59K | |
| 12001 | <1% | 539 | $58K | |
| 97597 | <1% | 524 | $57K | |
| 82948 | <1% | 8,781 | $56K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,403 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,883 | $55K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,509 | $54K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,713 | $53K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,670 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,178 | $48K |
| 97162 | <1% | 1,324 | $45K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 293 | $44K |
| 36591 | <1% | 1,981 | $44K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,407 | $39K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,347 | $38K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,582 | $37K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 1,457 | $36K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 467 | $32K |
| 86900 | <1% | 4,021 | $32K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 594 | $31K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 647 | $31K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,150 | $29K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,909 | $29K |
| 10060 | <1% | 192 | $28K | |
| 94060 | <1% | 312 | $27K | |
| 97161 | <1% | 315 | $27K | |
| 82805 | <1% | 740 | $26K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,652 | $25K |
| 85610 | <1% | 8,972 | $25K | |
| 97167 | <1% | 258 | $25K | |
| 70486 | <1% | 438 | $25K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,950 | $24K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,167 | $23K |
| 96523 | <1% | 943 | $22K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 857 | $22K |
| 96376 | <1% | 4,897 | $21K | |
| 84484 | <1% | 11,680 | $21K | |
| 84112 | <1% | 113 | $21K | |
| 83735 | <1% | 9,628 | $20K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 359 | $19K |
| 86901 | <1% | 3,978 | $19K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,082 | $18K |
| 86403 | <1% | 1,097 | $18K | |
| 73630 | <1% | 1,235 | $18K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,934 | $16K |
| 74018 | <1% | 1,092 | $16K | |
| 73610 | <1% | 947 | $16K | |
| 87210 | <1% | 2,605 | $15K | |
| 73564 | <1% | 1,124 | $15K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,836 | $15K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 254 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,456 | $14K |
| 82550 | <1% | 5,449 | $14K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,755 | $14K |
| 72131 | <1% | 271 | $13K | |
| 73130 | <1% | 767 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,506 | $13K |
| 87077 | <1% | 2,596 | $13K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 90 | $12K |
| 85730 | <1% | 7,285 | $12K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,248 | $12K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 203 | $12K |
| 36430 | <1% | 153 | $12K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,189 | $11K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,893 | $11K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 94 | $11K |
| 87070 | <1% | 1,263 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 182 | $11K |
| 93971 | <1% | 718 | $10K | |
| 93017 | <1% | 349 | $10K | |
| 97168 | <1% | 77 | $10K | |
| 73030 | <1% | 887 | $10K | |
| 93975 | <1% | 563 | $10K | |
| 84100 | <1% | 1,411 | $9K | |
| 73110 | <1% | 541 | $9K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,712 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,262 | $9K |
| 84550 | <1% | 1,116 | $9K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,139 | $9K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $8K |
| 77336 | <1% | 57 | $8K | |
| 85027 | <1% | 1,651 | $8K | |
| C1769 | Guide wire | <1% | 288 | $8K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $7K |
| 99152 | <1% | 528 | $7K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 34 | $7K |
| 86140 | <1% | 2,420 | $6K | |
| 83605 | <1% | 2,651 | $6K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 165 | $6K |
| 83690 | <1% | 8,535 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,111 | $6K |
| 87040 | <1% | 4,054 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,134 | $6K |
| 99153 | Mod sedat endo service >5yrs | <1% | 232 | $6K |
| 80074 | <1% | 187 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 943 | $5K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 62 | $5K |
| 87186 | <1% | 3,016 | $5K | |
| 82077 | <1% | 2,482 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 501 | $5K |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 245 | $4K |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 230 | $4K |
| 85379 | <1% | 2,151 | $4K | |
| 83880 | <1% | 1,602 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,991 | $4K |
| 29125 | <1% | 64 | $4K | |
| 82552 | <1% | 2,026 | $4K | |
| 80061 | Lipid panel | <1% | 1,449 | $4K |
| 93970 | <1% | 166 | $3K | |
| 97116 | <1% | 286 | $3K | |
| 80197 | <1% | 199 | $3K | |
| 73502 | <1% | 133 | $3K | |
| 85007 | <1% | 179 | $3K | |
| 72170 | <1% | 442 | $3K | |
| 73590 | <1% | 182 | $2K | |
| 12002 | <1% | 30 | $2K | |
| 90714 | <1% | 776 | $2K | |
| 73140 | <1% | 61 | $2K | |
| 87420 | <1% | 212 | $2K | |
| 73090 | <1% | 127 | $2K | |
| 87205 | <1% | 645 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 379 | $2K |
| 97166 | <1% | 61 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,207 | $2K |
| 76801 | <1% | 123 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,333 | $2K |
| 70491 | <1% | 13 | $2K | |
| 73080 | <1% | 78 | $2K | |
| 95819 | <1% | 33 | $1K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 381 | $1K |
| 74174 | <1% | 13 | $1K | |
| 88312 | <1% | 192 | $1K | |
| 80143 | <1% | 510 | $1K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 32 | $994.83 |
| 82728 | <1% | 406 | $992.77 | |
| 85652 | <1% | 866 | $974.85 | |
| 84439 | <1% | 420 | $894.47 | |
| 80179 | <1% | 456 | $867.61 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 35 | $859.72 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 508 | $733.69 |
| 72100 | <1% | 73 | $697.52 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 16 | $654.23 |
| 82247 | <1% | 145 | $642.72 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,014 | $603.59 |
| 71250 | <1% | 15 | $514.62 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 113 | $489.04 |
| 83540 | <1% | 201 | $481.06 | |
| 83550 | <1% | 165 | $468.33 | |
| 74019 | <1% | 15 | $459.28 | |
| 82140 | <1% | 162 | $428.95 | |
| 72110 | <1% | 13 | $419.52 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 456 | $401.14 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 150 | $386.27 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 36 | $348.67 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 364 | $338.34 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 172 | $290.64 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 48 | $237.07 |
| 76937 | <1% | 18 | $224.56 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,053 | $208.33 |
| 76820 | <1% | 353 | $194.04 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 96 | $180.88 |
| 90715 | <1% | 103 | $155.68 | |
| 87807 | <1% | 3,487 | $141.21 | |
| 71101 | <1% | 14 | $117.64 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 219 | $114.76 |
| 82607 | <1% | 225 | $104.62 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 43 | $93.62 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 52 | $82.80 |
| 84132 | <1% | 270 | $75.23 | |
| 94729 | <1% | 162 | $74.87 | |
| 86308 | <1% | 12 | $74.66 | |
| 94726 | <1% | 159 | $72.21 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 26 | $65.20 |
| T1017 | Case management, billed per 15 minutes | <1% | 26 | $61.28 |
| 83615 | <1% | 315 | $36.95 | |
| G0008 | Administration of influenza virus vaccine | <1% | 29 | $29.03 |
| 90686 | <1% | 35 | $20.58 | |
| 84145 | <1% | 16 | $17.91 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 183 | $16.92 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 185 | $13.19 |
| 82565 | <1% | 108 | $11.80 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 27 | $4.98 |
| 82248 | <1% | 31 | $4.60 | |
| 85044 | <1% | 38 | $1.98 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 116 | $0.00 |
| 86592 | 0% | 62 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 13 | $0.00 |
| 72128 | 0% | 14 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 15 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 14 | $0.00 |
| 82435 | 0% | 73 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 82 | $0.00 |
| 96368 | 0% | 148 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 58 | $0.00 |
| 82746 | 0% | 19 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 16 | $0.00 |
| 76830 | Ultrasound, transvaginal | 0% | 15 | $0.00 |
| 82947 | 0% | 90 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 17 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 62 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 424 | $0.00 |
| 96417 | 0% | 84 | $0.00 | |
| 84520 | 0% | 73 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 72 | $0.00 |
| 84295 | 0% | 73 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 123 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 19 | $0.00 |
| 36600 | 0% | 22 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 13 | $0.00 |
| 00731 | 0% | 12 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| 82010 | 0% | 14 | $0.00 | |
| 94150 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPEBURN, ERIC (CFO)
| Provider | Location | Paid |
|---|---|---|
| Medical Center of Deltona, INC. | Deltona, FL | $3.35M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.